Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) has confirmed that that Daniel Soland, who has has been involved with Idera as a consultant is set to join the Company on January 4, 2021, at the positions of Senior Vice President and COO. In his position as COO, as Idera plans to excel in expecting results from its cornerstone trial, ILLUMINATE-301, which is currently anticipated in the first quarter of 2021, he will be responsible for commercial planning and production.
In the biotechnology industry, Mr. Soland is a seasoned leader. Most lately, he served as the CEO of uniQure N.V and before that Senior Vice President & COO of ViroPharma Inc., While overseeing the commercial, engineering, and performance departments at ViroPharma. Mr. Soland helped develop the business infrastructure of the firm in the U.S., Europe, and Canada, and oversaw the launching of Cinryze, one of the most popular U.S. ultra-orphan drug launches.
Mr. Soland also served as Chairman and CEO of Epigenesis Pharmaceuticals from 2002 to 2005. Earlier in his career, he served as Vice President and Director, Worldwide Marketing Operations, GSK Biologicals and with GlaxoSmithKline. Mr. Soland completed his Bachelors of science From the University of Iowa in Pharmacy.
Idera has also revealed that the Senior Vice President of Business Growth and Strategic Planning, Clayton Fletcher, will depart at the end of 2020. Mr. Fletcher still will retain the position to lead business development activities as a consultant with the Group.
In February 2015, Mr. Fletcher joined Idera and his job was overseeing the market growth, portfolio management, planning, and business operations activities of the firm.
